SCHEMBL20743039

SCHEMBL20743039

CNC(=O)CC(Nc1nc2c(COC)cccc2[nH]1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SOS1 Q07889 6/20 0.41
▸ HDAC1 Q13547 6/20 0.40
▸ HDAC6 Q9UBN7 6/20 0.40
▸ HDAC5 Q9UQL6 6/20 0.40
▸ HDAC8 Q9BY41 4/20 0.40
▸ GRIN1 Q05586 1/20 0.37
▸ GRIN2B Q13224 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TEK Q02763 1/20 0.34
▸ ITGA5 P08648 1/20 0.34
▸ ITGB6 P18564 1/20 0.34
▸ ITGB8 P26012 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30645040 1.00 SOS1 (0.41) SOS1HDAC1HDAC6HDAC5HDAC8
SCHEMBL20743152 0.91 HDAC1 (0.37) SOS1HDAC1HDAC6HDAC5HDAC8
SCHEMBL20743145 0.89 SOS1 (0.41) SOS1HDAC1HDAC6HDAC5HDAC8
SCHEMBL30645123 0.89 SOS1 (0.41) SOS1HDAC1HDAC6HDAC5HDAC8
SCHEMBL30645115 0.88 SOS1 (0.46) SOS1HDAC1HDAC6HDAC5HDAC8
SCHEMBL20743101 0.88 SOS1 (0.46) SOS1HDAC1HDAC6HDAC5HDAC8
SCHEMBL20744168 0.86 SOS1 (0.43) SOS1ALDH1A1ITGA5ITGB6ITGB8
SCHEMBL30645108 0.86 SOS1 (0.43) SOS1ALDH1A1ITGA5ITGB6ITGB8
SCHEMBL20743761 0.83 NPC1 (0.47) SOS1SMN1; SMN2HTTKMT2AITGA5
SCHEMBL30645019 0.83 NPC1 (0.47) SOS1SMN1; SMN2HTTKMT2AITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111344281-B Potassium channel inhibitors substituted benzimidazoles 阿塞西翁制药公司 2023-11-14 — — CN claimed
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-07-09 — — US claimed
EP-3668841-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2020-06-24 — — EP claimed
WO-2019034603-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2019-02-21 — — WO claimed
CN-111344281-B Potassium channel inhibitors substituted benzimidazoles 阿塞西翁制药公司 2023-11-14 — — CN disclosed
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-07-09 — — US disclosed
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-07-09 — — US disclosed
EP-3668841-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2020-06-24 — — EP disclosed
WO-2019034603-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216398-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN1, KCNN2, KCNJ2 SOS1 3161/4885HDAC1 614/4885HDAC6 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback